Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Sopranos Pharmaceuticals for the quarter and full year 2025 financial results conference call. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session. Instructions will follow at this time. As a reminder, this conference is being recorded. I would now like to hand the conference over to Peter Bozzo of ICR Healthcare, Investor Relations Representative for Sopranos Pharmaceuticals. You may now begin. Thank you, Antoine. Good afternoon, everyone, and thank you for joining us today for Sopernos Pharmaceutical's fourth quarter and full year 2025 financial results conference call. Today, after the close of market, the company issued a press release announcing these results. On the call with me today are Sopernos' Chief Executive Officer, Jack Attar, and Chief Financial Officer, Tim Deck. These calls being made available via the investor relations section of the company's website at www.ir.sopernis.com. During the course of this call, management may make certain forward-looking statements regarding future events and the company's future performance. These forward-looking statements reflect Sopernis' current perspective on existing trends and information. Any such forward-looking statements are not guaranteed of future performance They involve risks and uncertainties, including those noted in the risk factor section of the company's latest SEC filings. As a result, may differ materially from those projected in this forward-looking statement. For the benefit of those of you who may be listening to the replay, this call is being held to record it on February 24th, 2026. Since then, the company may have made additional announcements related to the topics discussed. Please reference the company's...